Chitosan-TPP Nanoparticles Stabilized by Poloxamer for Controlling the Release and Enhancing the Bioavailability of Doxazosin Mesylate: In Vitro, and In Vivo Evaluation.
CONCLUSIONS: The study proved that controlling the release of DM from NPs enhance its bioavailability and improve the compliance of patients with hypertension or benign prostatic hyperplasia.
PMID: 30884977 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
More News: Benign Prostatic Hyperplasia | Doxazosin | Drugs & Pharmacology | Hypertension | Nanotechnology | Sodium | Study